The use of XRCC1 gene polymorphisms as predictive factor of clinical outcomes in personalized chemotherapy treatment for lung cancer patients might need to be investigated more carefully in well-designed pharmacogenetics and functional studies with large sample sizes in diverse ethnic populations to ensure a more accurate and robust conclusion in the future. Here, XRCC1 is linked to lung cancer.